|
EffRx’s most advanced project is
focused on the development and
commercialization of an effervescent
formulation of Alendronate, an
effective osteoporosis drug (EX101).
EffRx’s product pipeline includes
several other products in different
therapeutic areas including acute
migraine, and supportive oncology
products, is formulated to be a
"Best in Class" product by dosing
and reduced. The prime target
is to, in a positive health economic
way, address the well documented
compliance problem in this class of
drugs.
EX101
(effervescent alendronate) is
formulated to offer more convenient
dosing and reduced GI side effects
in all patients and especially for
those who do not tolerate Fosamax®
and other bisphosphonate tablets
(see illustration and data from
pH-telemetry study).
EX101
product features:
• No tablet to swallow
(leading issue when FDA mandated 30-60 minutes vertical waiting time
for oral bisphosphonates)
• Soluble Form means
there is no tablet to lodge in the
esophagus; EX101 is fully rinsed
into the stomach
• EX101
is administered in half the volume
of water (120 ml) compared with
dosing recommendation for the tablet
• It
is accepted that bisphosphonates in
the presence of acid (below pH 3)
can cause mucosal injury.
• Gastric
Imaging and pH Telemetry Clinical Study
[read more]
demonstrates
o Significantly
reduced stomach acidity after
dosing with EX101, pH stays
above 3
o Alendronate as a
result is never present in the
acid form, which has been shown
to be a gastric irritant
• Gastric Imaging & pH Telemetry
Clinical Study provide
key supportive data to
eliminate or reduce
vertical wait time |
